
CJC-1295 No DAC / Ipamorelin
5/5 mg
Combined GHRH analog and secretagogue receptor agonist preparation for dual-input pituitary research.
Free U.S. shipping $175+

CJC-1295 without DAC — also referred to as modified GRF (1–29) — is a GHRH analog carrying four amino-acid substitutions that improve resistance to enzymatic cleavage, but no albumin-binding group.
It is used in laboratory research as the short-duration counterpart to the DAC-modified version, allowing investigators to separate the contribution of sequence stabilization from the contribution of albumin binding.
For research use only — not for human or animal consumption.
Supplied solely for legitimate laboratory and research purposes. Not for medical or veterinary use, diagnosis, treatment, or prevention of disease.
Analytical values reflect per-lot documentation and appear once a batch is released.
Topics reflect published preclinical and in vitro research. Reference only — not a claim of clinical outcomes.
CJC-1295 No DAC is supplied for in vitro laboratory research. Batch-specific analytical documentation is provided when available for the released lot.

5/5 mg
Combined GHRH analog and secretagogue receptor agonist preparation for dual-input pituitary research.

5 mg
GHRH analog with Drug Affinity Complex modification for extended-duration receptor research.

10 mg
Second-generation growth hormone releasing peptide studied as a ghrelin receptor agonist reference.

10 mg
Early growth hormone releasing hexapeptide widely cited as a ghrelin receptor research standard.